Hepatitis B virus infection--natural history and clinical consequences.

This review article examines the structure and replication cycle of hepatitis B virus and discusses the natural history of primary infection, the mechanisms of clearance of the virus, and reasons for persistent infection. It concludes with a discussion of what we know about the virus and how it causes hepatitis and the implications for treatment.

[1]  A. Prince,et al.  Infectivity of blood from PCR‐positive, HBsAg‐negative, anti‐HBs‐positive cases of resolved hepatitis B infection , 2001, Transfusion.

[2]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[3]  R. Tedder,et al.  Evidence for a dynamic host‐parasite relationship in e‐negative hepatitis B carriers , 2002, Journal of medical virology.

[4]  D. S. Dane,et al.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. , 1970, Lancet.

[5]  G. Jay,et al.  HBx gene of hepatitis B virus induces liver cancer in transgenic mice , 1991, Nature.

[6]  K. Molnar-Kimber,et al.  Viral nucleic acid synthesis and antigen accumulation in pancreas and kidney of Pekin ducks infected with duck hepatitis B virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[8]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[9]  F. Chisari.  Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. , 1996, Current topics in microbiology and immunology.

[10]  A. Prince,et al.  IMMUNOHISTOCHEMICAL STUDIES ON THE ETIOLOGY OF ANICTERIC HEPATITIS IN KOREA. , 1964, American journal of hygiene.

[11]  M. Manns,et al.  In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil , 2001, Antimicrobial Agents and Chemotherapy.

[12]  G. Fourel,et al.  Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours , 1990, Nature.

[13]  P. Hofschneider,et al.  The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene , 1992, Journal of virology.

[14]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[15]  A. Prince,et al.  TIlE ETIOLOGY OF CHRlIONIC ACTIVE HEPATITIS IN KOREA PLATE , 2008 .

[16]  A M Prince,et al.  An antigen detected in the blood during the incubation period of serum hepatitis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Beasley,et al.  Vertical transmission of hepatitis B antigen in Taiwan. , 1975, The New England journal of medicine.

[18]  B. Gazzard,et al.  An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals , 2003, AIDS.

[19]  F Tsuda,et al.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen , 1990, Journal of virology.

[20]  R. Sprengel,et al.  Replication strategy of human hepatitis B virus , 1987, Journal of virology.

[21]  R. Purcell,et al.  Hepatitis B virus infection in chimpanzees: titration of subtypes. , 1975, The Journal of infectious diseases.

[22]  B. Tennant,et al.  Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. , 1988, Virology.

[23]  Nicholson,et al.  Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir , 2000, Journal of viral hepatitis.

[24]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[25]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[26]  Ruy M Ribeiro,et al.  Dynamics of hepatitis B virus infection. , 2002, Microbes and infection.

[27]  Marion Pl.  Use of animal models to study hepatitis B virus. , 1988 .

[28]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[29]  P. Tebas,et al.  Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. , 2002, The Journal of infectious diseases.

[30]  Prince Am,et al.  The etiology of chronic active hepatitis in Korea. , 1979 .

[31]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[32]  T. Tokino,et al.  Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. , 1990, Molecular biology & medicine.

[33]  G. Meucci,et al.  The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers , 1993, Annals of Internal Medicine.

[34]  E. Wiedenmann,et al.  Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). , 2000, Journal of virological methods.

[35]  F. Zoulim,et al.  Woodchuck hepatitis virus X protein is required for viral infection in vivo , 1994, Journal of virology.

[36]  E. De Clercq,et al.  5′-Nor Carbocyclic 5′-Deoxy-5′-(Isobutylthio)Adenosine and a 2′,3′-Dideoxy-2′,3′-Didehydro Derivative , 2001, Antiviral chemistry & chemotherapy.

[37]  J. Summers,et al.  Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Schinazi,et al.  Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection , 2001, Antimicrobial Agents and Chemotherapy.

[39]  T. Wright,et al.  Clinical aspects of hepatitis B virus infection , 1993, The Lancet.

[40]  M. Imai,et al.  Immunochemical structure of hepatitis B e antigen in the serum. , 1983, Journal of immunology.

[41]  R. Bruno,et al.  Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. , 2002, AIDS reviews.

[42]  R. Locksley,et al.  Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. , 2002, Immunity.

[43]  I. Millman,et al.  Virus-like particles in Australia antigen-associated hepatitis. , 1972 .

[44]  N. Leung,et al.  Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen‐negative chronic hepatitis B virus‐infected patients , 2002, Journal of viral hepatitis.

[45]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[46]  H. Alter,et al.  A "NEW" ANTIGEN IN LEUKEMIA SERA. , 1965, JAMA.

[47]  A. Prince,et al.  ANICTERIC HEPATITIS IN KOREA. II. SERIAL HISTOLOGIC STUDIES. , 1964, Archives of internal medicine.

[48]  M. Manns,et al.  In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 2001, Antimicrobial agents and chemotherapy.

[49]  H. Will,et al.  Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[51]  S. Krugman,et al.  Viral hepatitis. New light on an old disease. , 1970, JAMA.

[52]  D. Ganem,et al.  The role of envelope proteins in hepatitis B virus assembly. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Seeger,et al.  Novel mechanism for reverse transcription in hepatitis B viruses , 1993, Journal of virology.

[54]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[55]  J. Kao.  Hepatitis B viral genotypes: Clinical relevance and molecular characteristics , 2002, Journal of gastroenterology and hepatology.

[56]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[57]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[58]  J. Pollack,et al.  Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis , 1994, Journal of virology.

[59]  Y. Liaw,et al.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.

[60]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[61]  R. Purcell,et al.  Hepatocarcinogenicity of the woodchuck hepatitis virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[62]  U. Klingmüller,et al.  Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor , 1993, Journal of virology.

[63]  J. Summers,et al.  Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.

[64]  M. Timbury.  Infectious Hepatitis: Evidence for Two Distinctive Clinical, Epidemiological, and Immunological Types of Infection , 1997, Reviews in medical virology.

[65]  W. Szmuness,et al.  Immunologic distinction between infectious and serum hepatitis. , 1970, The New England journal of medicine.

[66]  R. Koff,et al.  Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. , 1977, Gastroenterology.

[67]  J. Cullen,et al.  Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte , 1994, Journal of virology.

[68]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[69]  J. Hoofnagle,et al.  Serologic Markers of Hepatitis B Virus Infection , 1986, Annual review of medicine.

[70]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[71]  C. Chu,et al.  The development of cirrhosis in patients with chronic type B hepatitis: A prospective study , 1988, Hepatology.

[72]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[73]  D. Ganem,et al.  Assembly of hepadnaviral virions and subviral particles. , 1991, Current topics in microbiology and immunology.

[74]  Illiam,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[75]  R. Schinazi,et al.  Antiviral beta-L-nucleosides specific for hepatitis B virus infection. , 2001, Antiviral chemistry & chemotherapy.

[76]  C. Gibbs,et al.  Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks , 2002, Hepatology.

[77]  F. Chisari,et al.  Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice , 1998, Journal of Virology.

[78]  A. Prince.  Relation of Australia and SH antigens. , 1968, Lancet.

[79]  J. Summers,et al.  Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells , 1986, Cell.

[80]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.

[81]  R. D. de Man,et al.  Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy , 2000, Hepatology.

[82]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[83]  L. Guillevin,et al.  Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. , 2001, Journal of autoimmunity.

[84]  K. Chayama,et al.  Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus , 1998, Cancer.

[85]  J. Gornbein,et al.  New Era of Liver Transplantation for Hepatitis B: A 17-Year Single-Center Experience , 2002, Annals of surgery.